MX2020003821A - Proceso de elaboración de espiroderivados. - Google Patents

Proceso de elaboración de espiroderivados.

Info

Publication number
MX2020003821A
MX2020003821A MX2020003821A MX2020003821A MX2020003821A MX 2020003821 A MX2020003821 A MX 2020003821A MX 2020003821 A MX2020003821 A MX 2020003821A MX 2020003821 A MX2020003821 A MX 2020003821A MX 2020003821 A MX2020003821 A MX 2020003821A
Authority
MX
Mexico
Prior art keywords
spiro derivatives
preparing spiro
methyl
intermediates
derivatives
Prior art date
Application number
MX2020003821A
Other languages
English (en)
Spanish (es)
Inventor
Michael Williams
Gerard M P Giblin
David T Macpherson
David R Witty
Osama Suleiman
Thierry Bonnaud
Richard Edwards
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of MX2020003821A publication Critical patent/MX2020003821A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10Salicylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Volume Flow (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2020003821A 2017-10-10 2018-10-10 Proceso de elaboración de espiroderivados. MX2020003821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570269P 2017-10-10 2017-10-10
PCT/US2018/055227 WO2019075073A2 (en) 2017-10-10 2018-10-10 PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES

Publications (1)

Publication Number Publication Date
MX2020003821A true MX2020003821A (es) 2023-01-12

Family

ID=66100090

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003821A MX2020003821A (es) 2017-10-10 2018-10-10 Proceso de elaboración de espiroderivados.
MX2022013928A MX2022013928A (es) 2017-10-10 2020-07-13 Proceso de elaboracion de espiroderivados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013928A MX2022013928A (es) 2017-10-10 2020-07-13 Proceso de elaboracion de espiroderivados.

Country Status (12)

Country Link
US (2) US11149039B2 (enExample)
EP (1) EP3694510A4 (enExample)
JP (1) JP2020536898A (enExample)
KR (1) KR20200068678A (enExample)
CN (1) CN111526874A (enExample)
AU (1) AU2018347349A1 (enExample)
CA (1) CA3077088A1 (enExample)
IL (1) IL273695A (enExample)
MA (1) MA50371A (enExample)
MX (2) MX2020003821A (enExample)
SG (1) SG11202002707VA (enExample)
WO (1) WO2019075073A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50371A (fr) 2017-10-10 2021-03-31 Biogen Inc Procédé de préparation de dérivés spiro

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US814396A (en) 1905-05-22 1906-03-06 Joseph R Russell Burner for liquid fuel.
KR0178475B1 (ko) * 1995-09-14 1999-03-20 윤덕용 신규한 n-비닐락탐 유도체 및 그의 중합체
DE60330456D1 (de) 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
GB0520578D0 (en) 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
CA2666136A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
AU2007307638A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2477964B1 (en) 2009-09-14 2015-02-11 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
US8618303B2 (en) * 2011-01-07 2013-12-31 Hoffmann-La Roche Inc. Pyrrolidine derivatives
PH12013501895A1 (en) * 2011-04-26 2013-10-14 Hoffmann La Roche Ethynyl derivatives as positive allosteric modulators of the mglur5
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds
HUE042064T2 (hu) * 2014-08-04 2019-06-28 Merck Patent Gmbh Pirrolidinon-származékok MetAP-2 inhibitorokként
SG11202002200UA (en) 2017-09-28 2020-04-29 Biogen Inc Novel salts
MA50371A (fr) 2017-10-10 2021-03-31 Biogen Inc Procédé de préparation de dérivés spiro

Also Published As

Publication number Publication date
EP3694510A2 (en) 2020-08-19
CN111526874A (zh) 2020-08-11
JP2020536898A (ja) 2020-12-17
US20200325144A1 (en) 2020-10-15
IL273695A (en) 2020-05-31
MA50371A (fr) 2021-03-31
KR20200068678A (ko) 2020-06-15
US20220033408A1 (en) 2022-02-03
EP3694510A4 (en) 2021-06-30
MX2022013928A (es) 2022-11-30
US11149039B2 (en) 2021-10-19
WO2019075073A2 (en) 2019-04-18
SG11202002707VA (en) 2020-04-29
AU2018347349A1 (en) 2020-04-23
WO2019075073A3 (en) 2020-04-02
CA3077088A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
MX2021007515A (es) Compuestos de heterociclil piridazina como fungicidas.
CL2015002343A1 (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
CO2018010877A2 (es) Ácido acrílico y métodos de producción del mismo
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
ECSP14020478A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
PE20150641A1 (es) Antagonistas del receptor st2l y metodos de uso
MX385450B (es) Procedimiento para la preparación de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo.
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
MX2017003131A (es) Metodo para la preparacion de 2-alcoxi ciclohexanol.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2017001131A1 (es) Síntesis de copanlisib y su sal diclorhidrato
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
MX2019006958A (es) Proceso para la preparacion de (s)-2-((2-((s)-4-(difluorometil)-2- oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida.
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
MX374300B (es) Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, métodos de preparación y usos.
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
EP3096762C0 (en) PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
CL2017001463A1 (es) Poliuretanos termoplásticos novedosos, uso de este material para la preparación de marcos en t para sistemas intrauterinos y marcos en t preparados con este material.
CO2019006395A2 (es) Polimorfos de sulfonamidas herbicidas
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX2020003821A (es) Proceso de elaboración de espiroderivados.